Y Intercept Hong Kong Ltd Boosts Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Y Intercept Hong Kong Ltd lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 265.4% in the fourth quarter, HoldingsChannel reports. The firm owned 9,132 shares of the company’s stock after purchasing an additional 6,633 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in IDEXX Laboratories were worth $3,776,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of IDXX. FSA Wealth Management LLC purchased a new position in IDEXX Laboratories during the third quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after buying an additional 57 shares during the period. Ashton Thomas Securities LLC purchased a new position in IDEXX Laboratories during the third quarter worth $37,000. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth $31,000. Finally, Kestra Investment Management LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth $38,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 0.0 %

Shares of IDXX opened at $452.77 on Monday. The firm has a market capitalization of $37.08 billion, a P/E ratio of 42.43, a P/E/G ratio of 3.41 and a beta of 1.37. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a fifty day moving average price of $431.92 and a 200-day moving average price of $452.18.

Analysts Set New Price Targets

Several research firms have commented on IDXX. Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Barclays lifted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Leerink Partners started coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Finally, Bank of America boosted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock worth $6,161,276 over the last three months. 2.11% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.